CompletedNot Applicable

ILIT: Follow-up of Rhinitis Quality of Life

Switzerland162 participantsStarted 2021-02-01

Plain-language summary

Re-evaluation of patients treated with intralymphatic immunotherapy (ILIT) in terms of quality of life and therapeutic efficacy and comparison with subcutaneous immunotherapy (SCIT) 15 years post immunotherapy

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Receiving ILIT or SCIT treatment at the USZ. * Indication: hay fever (type I sensitisation to grass pollen) * Adult male and female patients * Written/digital informed consent of the participating person * Complete return of both questionnaires Exclusion Criteria: * Discontinuation of immunotherapy * Incomplete data set * Pathological barrier (e.g. dementia) * Language barrier (not understanding the German language)

What they're measuring

Rhinoconjunctivitis quality of life

Timeframe: February 2021 through June 2021

Trial details

NCT IDNCT05037955

SponsorUniversity of Zurich

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-07-01

View on ClinicalTrials.gov More Allergic Rhinitis Due to Grass Pollen trials